Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: Cybin Inc. CYBN

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces FDA IND Authorization of Potentially Pivotal Study

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced that the U.S. Food and Drug Administration (“FDA”) has authorized an Investigational New Drug (“IND”) application to proceed with the company’s sponsored feasibility study. … Continue reading

Posted in Cybin Inc. CYBN | Leave a comment

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Files Patent Application Amid ‘New Era’ of Psychedelic Medicine

Substances such as psilocybin, ketamine and LSD are edging into mainstream culture, setting the stage for a paradigm shift in modern medicineCybin has filed an international patent application covering methods for the delivery of psychedelic medications by inhalationThe company is … Continue reading

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Completion of 74 In-Vitro and In-Vivo Evaluations of Expanding Portfolio

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has announced the completion of its 74th pre-clinical study as it continues to progress its proprietary psychedelic molecules into Investigational New Drug (“IND”)-enabling studies. According to … Continue reading

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Files International Patent Application in Continued Expansion of IP Portfolio

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced that it has filed an international patent application related to methods for the delivery of psychedelic medications by inhalation and devices for performing those methods. … Continue reading

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Poised Amid New Research Surrounding Psilocybin

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, is likely to benefit from new research touting psilocybin mental health treatments. According to recent news from a group of Yale … Continue reading

Posted in Cybin Inc. CYBN | Leave a comment

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces New Executives, Internal Promotions

Cybin names Dr. Amir Inamdar as chief medical officer for European operationsThe company appoints Dr. Geoff Varty as head of research and developmentBoth professionals bring decades of expertise to their new roles as Cybin focuses on progressing psychedelic therapeutics As … Continue reading

Posted in Cybin Inc. CYBN, Small Cap News | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Achievement of Adelia Milestones

Cybin (NYSE American: CYBN) (NEO: CYBN), a biotechnology company focused on psychedelic pharmaceutical therapies, has announced that Adelia Therapeutics Inc., a wholly-controlled subsidiary of Cybin, has achieved the milestones identified as “Year 2 Q1 (i)-(iii).” According to the update, the … Continue reading

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Present in Two Upcoming Investor Conferences

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, will be participating in two upcoming investor conferences. The company announced that CEO Doug Drysdale will be presenting virtually in a fireside chat during the Cantor Virtual … Continue reading

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Garners Attention as ‘Emerging Leader in the Psychedelic Therapeutics Space’

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, recently released its Q1 2021 operational and financial report for the period ended June 30, 2021. The biotech company hit several … Continue reading

Posted in Cybin Inc. CYBN | Leave a comment

MissionIRNewsBreaks – Cybin Inc.’s (NEO: CYBN) (NYSE American: CYBN) Recent Acquisition Boosting Psychedelic Drug Development Program

Cybin (NEO: CYBN) (NYSE American: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, announced its most recent acquisition and wholly controlled subsidiary, Adelia Therapeutics Inc., is already reporting success, having achieved certain milestones for … Continue reading

Posted in Cybin Inc. CYBN, MissionIRNewsBreaks | Leave a comment